Glycolytic System in Axons Supplement Decreased ATP Levels after Axotomy of the Peripheral Nerve

T Takenaka, Yu‐ichiro Ohnishi, Masamichi Yamamoto, Daiki Setoyama, Haruhiko KishimaeNeuro 2023 · DOI

Abstract

Wallerian degeneration (WD) occurs in the early stages of numerous neurologic disorders, and clarifying WD pathology is crucial for the advancement of neurologic therapies. ATP is acknowledged as one of the key pathologic substances in WD. The ATP-related pathologic pathways that regulate WD have been defined. The elevation of ATP levels in axon contributes to delay WD and protects axons. However, ATP is necessary for the active processes to proceed WD, given that WD is stringently managed by auto-destruction programs. But little is known about the bioenergetics during WD. In this study, we made sciatic nerve transection models for GO-ATeam2 knock-in rats and mice. We presented the spatiotemporal ATP distribution in the injured axons with in vivo ATP imaging systems, and investigated the metabolic source of ATP in the distal nerve stump. A gradual decrease in ATP levels was observed before the progression of WD. In addition, the glycolytic system and monocarboxylate transporters (MCTs) were activated in Schwann cells following axotomy. Interestingly, in axons, we found the activation of glycolytic system and the inactivation of the tricarboxylic acid (TCA) cycle. Glycolytic inhibitors, 2-deoxyglucose (2-DG) and MCT inhibitors, a-cyano-4-hydroxycinnamic acid (4-CIN) decreased ATP and enhanced WD progression, whereas mitochondrial pyruvate carrier (MPC) inhibitors (MSDC-0160) did not change. Finally, ethyl pyruvate (EP) increased ATP levels and delayed WD. Together, our findings suggest that glycolytic system, both in Schwann cells and axons, is the main source of maintaining ATP levels in the distal nerve stump.

Introduction

When a peripheral nerve is severed, the segment disconnected from the cell body undergoes Wallerian Degeneration (WD)—a programmed self-destruction process. While it is well-established that maintaining ATP levels can delay this decay, the exact bioenergetic source of that energy in an isolated axon has remained a mystery. Once an axon is cut, it is isolated from its primary source of proteins and organelles, and its mitochondria—the traditional "powerhouses"—quickly become dysfunctional. This study sought to identify how these dying axons maintain ATP levels for a short window after injury and whether manipulating these metabolic pathways could provide a therapeutic strategy to protect nerves.

Methods

The researchers employed a sophisticated toolkit to track energy levels in real-time:

  • FRET-based ATP Imaging: They used GO-ATeam2 knock-in rats and mice expressing a fluorescent biosensor that changes color based on ATP concentration, allowing for in vivo spatiotemporal mapping.
  • Two-Photon Microscopy: This enabled high-resolution imaging of ATP distribution within longitudinal sections of the sciatic nerve.
  • Mass Spectrometry: Used to quantify specific metabolites (like glucose, pyruvate, and lactate) and confirm metabolic shifts.
  • Pharmacological Intervention: The team used specific inhibitors to block different energy production pathways: 2-DG (glycolysis), 4-CIN (monocarboxylate transporters/MCTs), and MSDC-0160 (mitochondrial pyruvate carriers).
  • Supplementation: They tested whether Ethyl Pyruvate (EP) could rescue axonal ATP and delay degeneration.

Results

Spatiotemporal ATP Dynamics

In vivo imaging revealed that ATP levels in the distal stump do not vanish immediately. Instead, there is a gradual decrease over 24–48 hours before the rapid onset of physical degeneration.

Spatiotemporal ATP distribution and quantification in the sciatic nerve following transection. Panels (a) and (b) show short-term changes (minutes), while (c) and (d) show long-term dynamics (days).

The Metabolic Switch and Schwann Cell Support

As mitochondrial function (the TCA cycle) fails in the injured axon, the axon actively upregulates the glycolytic system to compensate. Immunohistochemistry showed a significant increase in glycolytic enzymes (HK-1, PFK-1, and LDHA) in both Schwann cells and axons after injury.

Schwann cells act as metabolic support units, ramping up glycolysis to produce monocarboxylates (like lactate and pyruvate). These fuels are then "shuttled" into the axons via Monocarboxylate Transporters (MCTs). Blocking these transporters (using 4-CIN) or glycolysis (using 2-DG) led to a further drop in ATP and accelerated nerve decay. Interestingly, inhibiting the transport of fuel into the mitochondria (via MPC inhibitors) did not significantly affect ATP levels, confirming that the axon moves past mitochondrial reliance post-injury.

Therapeutic Rescue

Supplementing the injured nerves with Ethyl Pyruvate (EP) successfully increased axonal ATP levels and significantly delayed the progression of Wallerian Degeneration, suggesting a potential clinical application for metabolic support in nerve trauma.

Discussion and Future Directions

These findings demonstrate that the glycolytic system, supported by a metabolic shuttle from Schwann cells, is the primary source of ATP in the distal nerve stump. While the in vivo imaging cannot perfectly distinguish between ATP signals originating in the axon versus the surrounding Schwann cells due to their tight intertwining, the pharmacological evidence strongly supports this cooperative model.

Future work will focus on using cell-specific promoters to express the ATP sensor in only one cell type at a time and investigating the specific signaling pathways triggered once the glycolytic system eventually fails. This metabolic support could eventually be leveraged to improve functional recovery in patients with peripheral nerve injuries or chronic neurodegenerative diseases.

Summary updated

Abstract

Wallerian degeneration (WD) occurs in the early stages of numerous neurologic disorders, and clarifying WD pathology is crucial for the advancement of neurologic therapies. ATP is acknowledged as one of the key pathologic substances in WD. The ATP-related pathologic pathways that regulate WD have been defined. The elevation of ATP levels in axon contributes to delay WD and protects axons. However, ATP is necessary for the active processes to proceed WD, given that WD is stringently managed by auto-destruction programs. But little is known about the bioenergetics during WD. In this study, we made sciatic nerve transection models for <i>GO-ATeam2</i> knock-in rats and mice. We presented the spatiotemporal ATP distribution in the injured axons with <i>in vivo</i> ATP imaging systems, and investigated the metabolic source of ATP in the distal nerve stump. A gradual decrease in ATP levels was observed before the progression of WD. In addition, the glycolytic system and monocarboxylate transporters (MCTs) were activated in Schwann cells following axotomy. Interestingly, in axons, we found the activation of glycolytic system and the inactivation of the tricarboxylic acid (TCA) cycle. Glycolytic inhibitors, 2-deoxyglucose (2-DG) and MCT inhibitors, a-cyano-4-hydroxycinnamic acid (4-CIN) decreased ATP and enhanced WD progression, whereas mitochondrial pyruvate carrier (MPC) inhibitors (MSDC-0160) did not change. Finally, ethyl pyruvate (EP) increased ATP levels and delayed WD. Together, our findings suggest that glycolytic system, both in Schwann cells and axons, is the main source of maintaining ATP levels in the distal nerve stump.
BibTeX
@inproceedings{takenaka2023glycolytic,
  author = {T Takenaka and Yu‐ichiro Ohnishi and Masamichi Yamamoto and Daiki Setoyama and Haruhiko Kishima},
  title = {{Glycolytic System in Axons Supplement Decreased ATP Levels after Axotomy of the Peripheral Nerve}},
  booktitle = {eNeuro},
  year = {2023},
  doi = {10.1523/eneuro.0353-22.2023},
}
Figure